bpc 157 safety concerns fda warning bpc-157 human clinical trials I'm sure your patients hit you up FDA panel narrowly backs unapproved

,

TB-4 (full-length thymosin 4, 43 aa) Moves repair cells (fibroblasts) into position and biases healing toward functional tissue rather than rope-like scarring. KPV Pre-empts the inflammation switch before it activates, so reactive skin doesnt drown the rebuilding signals

Loading phases may run 4 to 6 weeks at the higher end of the range, followed by a maintenance dose of 1 mg/day 3 to 5 times per week

Months 3-6 and beyond: Continued improvement and maintenance Improvement typically continues beyond the 12-week point, though the rate of change slows compared to the initial phase

Mild skin irritation may occur at the injection site